Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018103834) HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/103834 International Application No.: PCT/EP2016/080056
Publication Date: 14.06.2018 International Filing Date: 07.12.2016
IPC:
C12Q 1/68 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
Applicants:
FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA DE VALL D'HEBRON [ES/ES]; C. Natzaret 115 08035 Barcelona, ES
FUNDACIÓN SOLTI [ES/ES]; C. Balmes, 89 3º 7ª 08008 Barcelona, ES
FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA [ES/ES]; Avda. Catalunya, 21 46020 Valencia, ES
HOSPITAL CLÍNIC DE BARCELONA [ES/ES]; C. Villarroel 170 08036 Barcelona, ES
Inventors:
PRAT APARICIO, Aleix; ES
CORTÉS CASTÁN, Javier; ES
LLOMBART CUSSAC, Antonio; ES
Agent:
ZBM PATENTS - ZEA, BARLOCCI & MARKVARDSEN; Pl. Catalunya, 1 2nd floor 08002 Barcelona, ES
Priority Data:
Title (EN) HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY
(FR) HER2 EN TANT QUE PRÉDICTEUR DE RÉPONSE À UN BLOCAGE DE HER2 DOUBLE EN L'ABSENCE DE THÉRAPIE CYTOTOXIQUE
Abstract:
(EN) The present invention refers to an in vitro method for determining the efficacy of anti- HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.
(FR) La présente invention concerne un procédé in vitro de détermination de l'efficacité d'une thérapie anti-HER2 en l'absence de chimiothérapie chez un patient atteint d'un cancer du sein HER2+ comprenant la détection et/ou la quantification de l'expression de HER2 dans un échantillon biologique isolé du patient, (1) avant ou (2) pendant la thérapie anti-HER2 en l'absence de traitement chimiothérapeutique. La présente invention concerne également l'utilisation d'un produit d'expression génique de HER2 en tant que marqueur in vitro pour déterminer l'efficacité d'une thérapie anti-HER2 en l'absence de chimiothérapie chez un patient atteint d'un cancer du sein HER2+, ou en variante en tant que marqueur in vitro pour décider ou recommander s'il faut initier un régime médical alternatif à une thérapie anti-HER2 sans chimiothérapie chez un patient atteint d'un cancer du sein HER2+.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)